Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation Positive Advanced Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01544179
What this trial is testing

IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 265
Testing effectiveness (Phase 2)Study completedNCT04075396
What this trial is testing

Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 29
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Testing effectiveness (Phase 2)Looking for participantsNCT07538804
What this trial is testing

Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 294
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableStudy completedNCT04609319
What this trial is testing

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Who this might be right for
Lung Cancer
Pfizer 307
Large-scale testing (Phase 3)Study completedNCT03653546
What this trial is testing

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationBrain Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 492
Early research (Phase 1)Study completedNCT02157883
What this trial is testing

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 39
Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Large-scale testing (Phase 3)UnknownNCT02824458
What this trial is testing

Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Sun Yat-sen University 246
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410611
What this trial is testing

CtDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Who this might be right for
Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital 84
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Large-scale testing (Phase 3)Study completedNCT01814553
What this trial is testing

ADAM-Afatinib Diarrhea Assessment and Management

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 40
Large-scale testing (Phase 3)UnknownNCT04028778
What this trial is testing

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 310
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Early research (Phase 1)Looking for participantsNCT07315113
What this trial is testing

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc. 18
Next Page